114 related articles for article (PubMed ID: 25652004)
1. Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use.
von Stedingk K; De Preter K; Vandesompele J; Noguera R; Øra I; Koster J; Versteeg R; Påhlman S; Lindgren D; Axelson H
Int J Cancer; 2015 Aug; 137(4):868-77. PubMed ID: 25652004
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
[TBL] [Abstract][Full Text] [Related]
3. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC
J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472
[TBL] [Abstract][Full Text] [Related]
5. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
[TBL] [Abstract][Full Text] [Related]
6. 59-gene prognostic signature sub-stratifies high-risk neuroblastoma patients.
Vermeulen J; De Preter K; Laureys G; Speleman F; Vandesompele J
Lancet Oncol; 2009 Nov; 10(11):1030. PubMed ID: 19880060
[No Abstract] [Full Text] [Related]
7. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.
Schramm A; Schulte JH; Klein-Hitpass L; Havers W; Sieverts H; Berwanger B; Christiansen H; Warnat P; Brors B; Eils J; Eils R; Eggert A
Oncogene; 2005 Nov; 24(53):7902-12. PubMed ID: 16103881
[TBL] [Abstract][Full Text] [Related]
8. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
[TBL] [Abstract][Full Text] [Related]
9. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
10. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
[TBL] [Abstract][Full Text] [Related]
11. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
[TBL] [Abstract][Full Text] [Related]
12. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
13. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
15. Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group.
Teshiba R; Kawano S; Wang LL; He L; Naranjo A; London WB; Seeger RC; Gastier-Foster JM; Look AT; Hogarty MD; Cohn SL; Maris JM; Park JR; Shimada H
Pediatr Dev Pathol; 2014; 17(6):441-9. PubMed ID: 25207821
[TBL] [Abstract][Full Text] [Related]
16. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.
Wang LL; Teshiba R; Ikegaki N; Tang XX; Naranjo A; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Asgharzadeh S; Shimada H
Br J Cancer; 2015 Jun; 113(1):57-63. PubMed ID: 26035700
[TBL] [Abstract][Full Text] [Related]
17. Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.
Liu PY; Erriquez D; Marshall GM; Tee AE; Polly P; Wong M; Liu B; Bell JL; Zhang XD; Milazzo G; Cheung BB; Fox A; Swarbrick A; Hüttelmaier S; Kavallaris M; Perini G; Mattick JS; Dinger ME; Liu T
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906397
[TBL] [Abstract][Full Text] [Related]
18. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
19. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
20. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.
Alaminos M; Davalos V; Cheung NK; Gerald WL; Esteller M
J Natl Cancer Inst; 2004 Aug; 96(16):1208-19. PubMed ID: 15316056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]